US cuts fees for Covid-19 tests
Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
Toxicity concerns now hit the Covid antibody approach
An NIAID-sponsored study of a Lilly antibody has been paused for possible toxicity, prompting speculation over the cause of the problem.
J&J pause adds to adenovirus vaccine doubts
Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.
Biopharma shares keep riding the Covid wave
The pandemic remains the dominant storyline for drug stocks at the nine-month mark, with Vertex and Horizon rare non-Covid-related risers.
Two Covid-19 antibodies look better than one for Lilly
Lilly’s doublet might be superior to Regeneron’s cocktail, but timing and manufacturing issues could now come into play.
US cuts fees for Covid-19 tests
Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
Toxicity concerns now hit the Covid antibody approach
An NIAID-sponsored study of a Lilly antibody has been paused for possible toxicity, prompting speculation over the cause of the problem.
J&J pause adds to adenovirus vaccine doubts
Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.
Biopharma shares keep riding the Covid wave
The pandemic remains the dominant storyline for drug stocks at the nine-month mark, with Vertex and Horizon rare non-Covid-related risers.
Two Covid-19 antibodies look better than one for Lilly
Lilly’s doublet might be superior to Regeneron’s cocktail, but timing and manufacturing issues could now come into play.
